000306854 001__ 306854
000306854 005__ 20260107131028.0
000306854 0247_ $$2doi$$a10.1016/j.vaccine.2025.128059
000306854 0247_ $$2pmid$$apmid:41352221
000306854 0247_ $$2ISSN$$a0264-410X
000306854 0247_ $$2ISSN$$a1358-8745
000306854 0247_ $$2ISSN$$a1873-2518
000306854 037__ $$aDKFZ-2025-02831
000306854 041__ $$aEnglish
000306854 082__ $$a610
000306854 1001_ $$aNowzari, Fariborz$$b0
000306854 245__ $$aEvolution and trends in non-viral mRNA Cancer vaccines: A scoping review from 2015 to 2025.
000306854 260__ $$aAmsterdam$$bElsevier$$c2026
000306854 3367_ $$2DRIVER$$aarticle
000306854 3367_ $$2DataCite$$aOutput Types/Journal article
000306854 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1767787786_3267578$$xReview Article
000306854 3367_ $$2BibTeX$$aARTICLE
000306854 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000306854 3367_ $$00$$2EndNote$$aJournal Article
000306854 500__ $$aVolume 71, 25 January 2026, 128059 /  Epub 2025 Dec 5.
000306854 520__ $$aThis scoping review synthesizes clinical trials from 2015 to 2025 investigating non-viral messenger RNA (mRNA)-based cancer vaccines, emphasizing trends in delivery platforms-ex vivo dendritic cell (DC) vaccines versus in vivo lipid-based systems-and their association with cancer types. A systematic search of PubMed and ClinicalTrials.gov identified 72 early-phase trials, revealing a significant shift from DC-based ex vivo approaches (dominant 2015-2020) to lipid nanoparticle (LNP)-based in vivo delivery post-2021 (p = 0.0025), propelled by advancements from COVID-19 vaccines. Statistical analyses, including linear regression and Fisher's exact test, demonstrate a strong association between ex vivo delivery and brain/CNS cancers (p = 0.00042) and no significant correlation between DC vaccine administration routes and cancer types (p = 0.25). The surge in combination immunotherapies, particularly with immune checkpoint inhibitors post-2019, underscores the field's move toward multimodal strategies. This article offers a data-driven roadmap of the field's evolution, highlighting gaps in delivery optimization, reporting transparency, and standardization for future research. Companion articles detail ex vivo DC vaccine strategies and in vivo mRNA vaccine advancements.
000306854 536__ $$0G:(DE-HGF)POF4-314$$a314 - Immunologie und Krebs (POF4-314)$$cPOF4-314$$fPOF IV$$x0
000306854 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000306854 650_7 $$2Other$$aCancer
000306854 650_7 $$2Other$$aClinical trials
000306854 650_7 $$2Other$$aDendritic cells
000306854 650_7 $$2Other$$aImmunotherapy
000306854 650_7 $$2Other$$aLipid nanoparticles
000306854 650_7 $$2Other$$aNon-viral delivery
000306854 650_7 $$2Other$$aRNA vaccines
000306854 7001_ $$aNowzari, Farhad$$b1
000306854 7001_ $$aKian, Mehdi$$b2
000306854 7001_ $$aZahedi, Mohammadsaeid$$b3
000306854 7001_ $$0P:(DE-He78)55a22d494a544551b757eeed4cc5c0d1$$aSamimi, Kiana$$b4$$udkfz
000306854 7001_ $$aKarimzadeh, Alireza$$b5
000306854 7001_ $$aTanideh, Nader$$b6
000306854 7001_ $$aMussin, Nadiar M$$b7
000306854 7001_ $$aTamadon, Amin$$b8
000306854 773__ $$0PERI:(DE-600)1468474-3$$a10.1016/j.vaccine.2025.128059$$gVol. 71, p. 128059 -$$p128059$$tVaccine$$v71$$x0264-410X$$y2026
000306854 909CO $$ooai:inrepo02.dkfz.de:306854$$pVDB
000306854 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-28$$wger
000306854 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bVACCINE : 2022$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-28
000306854 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bVACCINE : 2022$$d2024-12-28
000306854 9141_ $$y2025
000306854 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)55a22d494a544551b757eeed4cc5c0d1$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000306854 9131_ $$0G:(DE-HGF)POF4-314$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImmunologie und Krebs$$x0
000306854 9201_ $$0I:(DE-He78)D410-20160331$$kD410$$lImmuntherapie und -prävention$$x0
000306854 980__ $$ajournal
000306854 980__ $$aVDB
000306854 980__ $$aI:(DE-He78)D410-20160331
000306854 980__ $$aUNRESTRICTED